https://www.selleckchem.com/pr....oducts/Benserazide-h
HbA1c significantly decreased in patients after 180 days of sensor wear (-0.43% ± 0.69%, 5 ± 8 mmol/mol, P less then 0.0001). As expected, CGM-naïve patients achieved the greatest reduction in HbA1c (-0.74% ± 0.48%, 8 ± 5 mmol/mol). TIR significantly increased and TAR and mean daily sensor glucose significantly decreased while TBR did not change after 180 days of sensor wear. CONCLUSIONS Real-world clinical use of the Eversense CGM System for 180 days was associated with significant improvements in HbA1c and
Like
Comment
Share
